Stephen Sherman

Stephen Sherman is a Scientist II specializing in stem cell therapies at Editas Medicine since February 2021, focusing on developing a toxicology program for the iPSC-derived natural killer cell program. Responsibilities include creating assays for residual iPSC detection, conducting tumorigenicity assays, assessing off-target cell functions, characterizing cell impurities, and collaborating with CROs for GLP toxicology studies. Previously, Stephen completed a postdoctoral fellowship at Harvard Medical School from March 2019 to July 2020, where a collaborative program with MIT was led to explore the effects of TLR3 agonists on colorectal cancer and the associated T-cell responses. Stephen holds a PhD in Physiology and Pharmacology from Western University, earned in 2019, and a Bachelor's degree in Genetics from the same institution, completed in 2014.